This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
3/10/2021
Good afternoon, and welcome to Protagonist Therapeutics' fourth and full year 2020 earnings conference call and audio webcast. At this time, all participants are in a listen-only mode. Please be advised that today's webcast is being recorded. If you require any further assistance, please press star zero. With that, I would like to hand the conference over to our first speaker, Don Kalkofen, Chief Financial Officer. Thank you, and please go ahead.
Thank you for joining us today. Thank you. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the risk factor sections of our annual report on Form 10-K for the year ended December 31, 2020, on file with the SEC. A question and answer session will follow the formal presentation. And just as a reminder, the call is being recorded. I'd now like to turn the call over to Dinesh Patel, President and CEO of Protagonist, to provide a company update.
Thank you, Don. Good afternoon, everyone, and thank you all for joining our conference call to discuss protagonist therapeutics, financial results, and corporate highlights for the fourth quarter and full year 2020. Don and I are joined on today's call by Samuel Sachs, our Chief Medical Officer, David Liu, our Chief Scientific Officer, and Sunil Gupta, Chief was an exceptional and transformative year for Protagonist, during which we expanded our clinical pipeline, and we now have five different new chemical entities, or NCEs, that are being advanced in six different clinical studies. And all of these studies are expected to be completed over the next two years. As many of you know, each of our clinical assets has been developed through our proprietary technology platform, and currently we are developing novel therapeutic options across three disciplines. various blood disorders influenced by excessive red blood cell production, that is excessive erythrocytosis, or by excessive iron overload conditions. Two, inflammatory bowel disease or IBD, such as Crohn's disease and ulcerative colitis. And three, various inflammatory and autoimmune diseases that have already been clinically validated by the interleukin-23 or IO-23 pathway. by reviewing Respartide, previously known as PTG300. As a reminder, Respartide is a peptide mimetic of the natural hormone hexidine, which is the key regulator of iron homeostasis, as it controls the absorption, storage, and distribution of iron in the body. Respartide was developed to have superior drug-like properties, including its potency, half-life, solubility, Our most advanced clinical program with this candidate is in patients with polycythemia vera, also known as PV, a rare and progressive blood disorder affecting about 160,000 patients in the United States alone. In May of 2020, we presented a very small but robust data set for seven patients from our ongoing phase two PV trial. And that proved to be a turning point for Protagonist. In December last year, in an oral presentation at the ASH conference, We shared the data for 18 patients from the same study and were pleased to see the continuation of the robust clinical responses observed earlier in May. To quickly recap the data, Rescortide appears to be safe, well-tolerated, and very effective in managing hematocrit control, below 45% across the 18 adult patients evaluated. This tight hematocrit control also led to a dramatic decrease in the need for therapeutic phlebotomy, the most common treatment modality for this condition. Furthermore, we also observed a reversal of ion deficiency in these patients. Ion deficiency is a typical undesired outcome of therapeutic phlebotomy in these patients. While phlebotomy is the current mainstay of PV treatment, many patients are unable to maintain hematocrit levels below and guidelines. And this is unfortunately true even for those patients receiving frequent lobotomies and receiving treatment with cytoreductive agents. So to develop a clear understanding of the current treatment regimen and evaluate its true effectiveness, last year we took a large scale retrospective analysis of real-world patients thousand patients, and we also obtained hematocrit measurements from blood test results for a subgroup of over 4,000 patients. Our findings were an eye-opener, and it showed that hematocrit levels were poorly managed for a majority of patients. In fact, only 22% of the patients on current treatments had consistent adherence to NCCN guidelines of keeping hematocrit below 45%. This is concerning at many levels, including the fact that with high hematocrit levels, PV patients may be exposed to higher risk of life-threatening thrombotic events. This analysis further confirms our belief that there is a large and glaring need for better treatment options for these PV patients. Based on our promising Phase II results, we believe that a natural hormone mimetic like and effective therapy that improves upon the standard of care options, not only for patients receiving treatment for phlebotomy, but also for patients who continue to receive phlebotomy in combination with other pharmaceutical treatments. Our ongoing Phase II Respiratized PV study is progressing on track. Recruitment has in fact recently accelerated, and we expect to complete the enrollment of 50 patients by mid-2021. With the compelling clinical trial data in hand, we are consulting with US regulatory authorities in the first half of 2021 to discuss and finalize Respotide has received fast-track designation for PV from the U.S. FDA and orphan drug designation from both the U.S. and European regulatory agencies. The advancement of Respotide to a pivotal trial in this indication will be a key turning point for Protagonist in 2021. treatment paradigm in PV and become the main long-term non-cyto-reductive therapy of choice for many patients living with this challenging condition. Now, resphatized clinical momentum does not stop at PV. We are also evaluating this candidate for hereditary hemochromatosis, or HH, is a disease characterized by iron overload where persistent iron overload can lead to heart and liver damage that could ultimately lead to more life-threatening situations. Today, HH impacts approximately 1 million patients in the U.S. and Canada, and phlebotomy is the only therapeutic option for these patients. There are no FDA-approved drugs for this indication. also underway by us to better understand which subpopulations of these 1 million HH patients may derive maximum benefit from a drug like Raspartide in comparison to subatomy. We are pleased with the progress of the current phase 2 study and we should be able to share preliminary results in the second half of the year. Based on these results, we will determine next steps and the path forward for Raspartide in the Beyond PV and HH, we are actively evaluating additional indications for Raspotide and plan to select one new therapeutic program for Raspotide in 2021. The core idea is to capitalize on the excellent clinical attributes of this natural hormone method and expand its utility to multiple diseases influenced by excessive ion accumulation or erythrocytosis in patients. We are also working on an oral hepatitis mematic, which may ultimately bring more convenience and preferred options to patients with certain conditions. Now, I would like to turn the conversation towards inflammatory bowel disease or IBD program. First, let us talk about our fully-owned SFPN 943 in the IBD space. PM943 is a first-in-class, orally delivered, gut-restricted antagonist of alpha-4-beta-7 integrin, a validated biological target for IBD. We believe the gut-restricted alpha-4-beta-7 integrin blockade is unique and potentially groundbreaking in treating IBD, as it allows us to achieve receptor target engagement directly and locally in the GITC compartment. More importantly, let me remind you that we have already established clinical proof of concept through a phase 2 study in patients with moderate to severe ulcerative colitis with our first generation drug PTG100. PN943 is our second generation drug that is at least three-fold more potent across all individuals. and efficacy that we have assembled to date. We continue to advance our 150-patient Phase II ideal study, evaluating the safety, tolerability, and efficacy of TN943 in ulcerative colitis. While we stopped providing guidance in 2021 for this study because of COVID-19 related impact on enrollment, we are very pleased with the current enrollment rates and are forecasting the completion of this global study in 2022. Finally, I'll discuss the ongoing strategic collaboration with Janssen Pharmaceuticals. The partnership was initiated three and a half years ago with a $50 million upfront, and now an additional $30 million has been earned so far from achievement of various milestones. It's a very rewarding deal structure with more milestones in the future, The Janssen Protagonist Partnership aims to discover and develop oral IR23 receptor antagonists with application in various diseases that could be approached with the blockade of the IR23 pathway. While the pathway is a validated therapeutic mechanism, orally delivered therapies for blocking this pathway have not yet been made available. With our collaboration with Janssen, we are working to change the treatment paradigm through differentiated assets that could facilitate transition from injectable to oral targeted therapy. In the past few months, we added two new entities, PN-235 and PN-232, to the clinical development program with Janssen, in addition to the first collaboration asset, PTG-200. A Phase I trial expected to be completed in the second half of 2021. Additionally, for PTG 200, enrollment continues for patients in a Phase II proof-of-concept study for Crohn's disease. All three candidates were discovered through our peptide technology platform, which further demonstrates our versatility in finding therapies where there are no protagonist. So in summary, we are incredibly excited with simultaneous progress in three specific categories. One, the Respiratide program for polycythemia vera and hereditary hemochromatosis. Two, advancement of the gut-restricted oral integrin blocker PN943 in ulcerative colitis. And three, progression of three and clinical development in partnership with Janssen to treat various inflammatory and autoimmune diseases. With that,
You're reading a preview of the PTGX Q4 2020 earnings call.
Free account.
